These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37414719)

  • 21. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moving towards a new era in the management of chronic immune thrombocytopenia.
    Wadenvik H; Olsson B
    Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury.
    Watanabe R; Tabayashi T; Tomikawa T; Sagawa M; Anan-Nemoto T; Kimura Y; Takahashi Y; Tokuhira M; Otaki S; Oi H; Sawano M; Sugiyama S; Kizaki M
    Int J Hematol; 2017 Jan; 105(1):100-103. PubMed ID: 27709451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes.
    Tiu RV; Sekeres MA
    Expert Opin Biol Ther; 2008 Jul; 8(7):1021-30. PubMed ID: 18549331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
    Doobaree IU; Newland A; McDonald V; Nandigam R; Mensah L; Leroy S; Seesaghur A; Patel H; Wetten S; Provan D
    Eur J Haematol; 2019 May; 102(5):416-423. PubMed ID: 30758874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.
    Cooper N; Hill QA; Grainger J; Westwood JP; Bradbury C; Provan D; Thachil J; Ramscar N; Roy A
    Acta Haematol; 2021; 144(4):418-426. PubMed ID: 33789275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current treatment of primary immune thrombocytopenia].
    Lozano ML; Vicente V
    Med Clin (Barc); 2014 May; 142(9):399-405. PubMed ID: 23809409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positioning new treatments in the management of immune thrombocytopenia.
    Arnold DM
    Pediatr Blood Cancer; 2013; 60 Suppl 1(Suppl 1):S19-22. PubMed ID: 23109488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
    Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
    Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
    Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
    J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombopoietin receptor agonists increase splenic regulatory T-cell numbers in immune thrombocytopenia.
    Pizzi M; Vianello F; Binotto G; Vianelli N; Carli G; Auteri G; Nichele I; Sbaraglia M; Zoletto S; Scarmozzino F; Bresciani R; d'Amore F; Friziero A; Guzzardo V; Bertozzi I; Famengo B; d'Amore ESG; Sabattini E; Dei Tos AP
    Br J Haematol; 2022 Sep; 198(5):916-922. PubMed ID: 35701886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium.
    Rovó A; Cantoni N; Samii K; Rüfer A; Koenen G; Ivic S; Cavanna D; Benz R
    PLoS One; 2022; 17(4):e0267342. PubMed ID: 35446925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Refractory immune thrombocytopenia in adults: Towards a new definition.
    Arnold DM; Clerici B; Ilicheva E; Ghanima W
    Br J Haematol; 2023 Oct; 203(1):23-27. PubMed ID: 37642211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials.
    Delshad M; Davoodi-Moghaddam Z; Pourbagheri-Sigaroodi A; Faranoush M; Abolghasemi H; Bashash D
    Thromb Res; 2024 Mar; 235():125-147. PubMed ID: 38335568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A proposal for new definition (s) and management approach to paediatric refractory ITP: Reflections from the Intercontinental ITP Study Group.
    Neunert C; Heitink-Polle KMJ; Lambert MP
    Br J Haematol; 2023 Oct; 203(1):17-22. PubMed ID: 37641973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential role of thrombopoietin in idiopathic thrombocytopenic purpura.
    von dem Borne A; Folman C; van den Oudenrijn S; Linthorst G; de Jong S; de Haas M
    Blood Rev; 2002 Mar; 16(1):57-9. PubMed ID: 11913997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
    Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.